The FDA Is Getting Ready for Radiopharma. Is the Industry? Industry Insights The FDA Is Getting Ready for Radiopharma. Is the Industry?
The Alpha Era: How 2026 Could Be the Breakthrough Year for Targeted Alpha Therapies Industry Insights The Alpha Era: How 2026 Could Be the Breakthrough Year for Targeted Alpha Therapies
Radiopharma Infrastructure in 2025: Lessons Learned & 2026 Outlook Industry Insights Radiopharma Infrastructure in 2025: Lessons Learned & 2026 Outlook
How to Mitigate CMC Risks and Avoid Delays in IND-Stage Radiopharma Development: A CDMO’s Perspective Industry Insights How to Mitigate CMC Risks and Avoid Delays in IND-Stage Radiopharma Development: A CDMO’s Perspective
What the FDA’s new draft guidance means for the radiopharmaceutical industry Industry Insights What the FDA’s new draft guidance means for the radiopharmaceutical industry
Five pitfalls that put radiopharma programs at risk early Industry Insights Five pitfalls that put radiopharma programs at risk early
Why radiopharmaceutical supply chain diversity matters Industry Insights Why radiopharmaceutical supply chain diversity matters
Get ahead of CMC hurdles before they derail your IND Industry Insights Get ahead of CMC hurdles before they derail your IND
How we’re solving one of radiopharma’s biggest barriers to adoption Industry Insights How we’re solving one of radiopharma’s biggest barriers to adoption
Ask the right questions at every stage to keep your radiopharmaceutical on track Industry Insights Ask the right questions at every stage to keep your radiopharmaceutical on track
